Premium
Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions
Author(s) -
Walker Lauren,
Stefanis Leonidas,
Attems Johannes
Publication year - 2019
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.14698
Subject(s) - dementia with lewy bodies , dementia , parkinson's disease , disease , lewy body , neuroscience , pathological , neuropathology , medicine , alpha synuclein , biomarker , psychology , pathology , psychiatry , biology , biochemistry
Lewy body diseases share clinical, pathological, genetic and biochemical signatures, and are regarded as a highly heterogeneous group of neurodegenerative disorders. Inclusive of Parkinson's disease ( PD ), Parkinson's disease dementia ( PDD ) and dementia with Lewy bodies ( DLB ), controversy still exists as to whether they should be considered as separate disease entities or as part of the same disease continuum. Here we discuss emerging knowledge relating to both clinical, and neuropathological differences and consider current biomarker strategies as we try to improve our diagnostic capabilities and design of disease modifying therapeutics for this group of debilitating neurodegenerative disorders.This article is part of the Special Issue “Synuclein”.